KORU Medical Systems (KRMD) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Entity Registrant Name	REPRO MED SYSTEMS INC
Entity Central Index Key	0000704440
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	0-12305
Entity Incorporation State Country Code	NY
Title of 12(b) Security	common stock, $0.01 par value
Trading Symbol	KRMD
Security Exchange Name	NASDAQ
Entity's Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		43,942,888
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

BALANCE SHEETS (Unaudited)

BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 32,433,811	$ 5,870,929
Accounts receivable less allowance for doubtful accounts of $24,676 and $32,645 at September 30, 2020 and December 31, 2019, respectively	3,736,596	3,234,521
Inventory	5,633,139	2,388,477
Prepaid expenses	844,496	387,396
TOTAL CURRENT ASSETS	42,648,042	11,881,323
Property and equipment, net	1,260,675	611,846
Patents, net of accumulated amortization of $335,686 and $288,967 at September 30, 2020 and December 31, 2019, respectively	884,635	807,135
Right of use assets, net	271,679	373,734
Deferred tax asset	349,609	188,241
Other assets	19,812	19,582
TOTAL ASSETS	45,434,452	13,881,861
CURRENT LIABILITIES
Accounts payable	1,363,070	572,656
Accrued expenses	3,051,582	1,296,612
Accrued payroll and related taxes	440,144	190,265
Accrued tax liability	363,158	204,572
Finance lease liability - current	3,026	5,296
Operating lease liability - current	140,450	136,888
TOTAL CURRENT LIABILITIES	5,361,430	2,406,289
Finance lease liability, net of current portion	414	2,646
Operating lease liability, net of current portion	131,229	236,846
TOTAL LIABILITIES	5,493,073	2,645,781
Commitments and contingencies (Refer to Note 3)
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 46,671,807 and 42,239,788 shares issued, 43,934,576 and 39,502,557 shares outstanding at September 30, 2020 and December 31, 2019, respectively	466,718	422,398
Additional paid-in capital	35,331,483	6,293,069
Treasury stock, 2,737,231 shares at September 30, 2020 and December 31, 2019, respectively, at cost	(344,204)	(344,204)
Retained earnings	4,487,382	4,864,817
TOTAL STOCKHOLDERS' EQUITY	39,941,379	11,236,080
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 45,434,452	$ 13,881,861

BALANCE SHEETS (Unaudited) (Par

BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 24,676	$ 32,645
Patents, accumulated amortization	$ 335,686	$ 288,967
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	75,000,000	75,000,000
Common stock, issued	46,671,807	42,239,788
Common stock, outstanding	43,934,576	39,502,557
Treasury stock	2,737,231	2,737,231

STATEMENTS OF OPERATIONS (Unaud

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
NET SALES	$ 6,080,315	$ 6,617,397	$ 20,119,228	$ 16,940,487
Cost of goods sold	2,139,592	2,234,489	7,480,415	6,033,961
Gross Profit	3,940,723	4,382,908	12,638,813	10,906,526
OPERATING EXPENSES
Selling, general and administrative	3,075,169	2,441,381	9,039,980	6,976,684
Litigation	675	864,009	2,446,747	2,481,471
Research and development	390,416	170,260	944,637	450,454
Depreciation and amortization	115,637	82,774	297,801	252,594
Total Operating Expenses	3,581,897	3,558,424	12,729,165	10,161,203
Net Operating Profit/(Loss)	358,826	824,484	(90,352)	745,323
Non-Operating Income/(Expense)
Gain/(Loss) on currency exchange	1,927	(9,358)	(11,164)	(20,283)
Gain on disposal of fixed assets, net	22,113		16,591	49,740
Interest income, net	9,662	23,368	23,690	59,091
TOTAL OTHER INCOME/(EXPENSE)	33,702	14,010	29,117	88,548
INCOME/(LOSS) BEFORE INCOME TAXES	392,528	838,494	(61,235)	833,871
Income Tax Expense	(143,353)	(186,681)	(316,200)	(189,265)
NET INCOME/(LOSS)	$ 249,175	$ 651,813	$ (377,435)	$ 644,606
NET INCOME/(LOSS) PER SHARE
Basic (in dollars per share)	$ 0.01	$ 0.02	$ (0.01)	$ 0.02
Diluted (in dollars per share)	$ 0.01	$ 0.02	$ (0.01)	$ 0.02
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic (in shares)	43,914,542	39,022,298	41,326,815	38,534,021
Diluted (in shares)	44,119,511	39,298,408	41,326,815	38,734,083

STATEMENTS OF CASH FLOWS (Unaud

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)/Income	$ (377,435)	$ 644,606
Adjustments to reconcile net (loss)/income to net cash provided by/(used in) operating activities:
Stock-based compensation expense	1,191,146	897,300
Stock-based litigation settlement expense	1,285,102
Depreciation and amortization	297,801	252,594
Deferred capital gain - building lease		(3,763)
Deferred taxes	(161,368)	134,563
Gain on disposal of fixed assets	(16,591)	(49,740)
Changes in operating assets and liabilities:
Increase in accounts receivable	(502,075)	(2,120,780)
Increase in inventory	(3,244,662)	(634,803)
Increase in prepaid expenses and other assets	(457,330)	(206,560)
Increase in accounts payable	790,414	421,479
Increase/(Decrease) in accrued payroll and related taxes	249,879	(310,355)
Increase in accrued expenses	1,754,970	490,053
Increase/(Decrease) in accrued tax liability	158,586	(16,608)
NET CASH PROVIDED BY/(USED IN) OPERATING ACTIVITIES	968,437	(502,014)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(908,323)	(158,193)
Purchases of patents	(124,216)	(188,274)
Proceeds from disposal of property and equipment	25,000	217,821
Proceeds from certificate of deposit		1,517,927
NET CASH (USED IN)/PROVIDED BY INVESTING ACTIVITIES	(1,007,539)	1,389,281
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of equity	26,606,486	508,900
Payments for cancelled shares		(2,820)
Borrowings from indebtedness	4,976,508
Payments on indebtedness	(4,976,508)
Payments on finance lease liability	(4,502)	(3,122)
NET CASH PROVIDED BY FINANCING ACTIVITIES	26,601,984	502,958
NET INCREASE IN CASH AND CASH EQUIVALENTS	26,562,882	1,390,225
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,870,929	3,738,803
CASH AND CASH EQUIVALENTS, END OF PERIOD	32,433,811	5,129,028
Cash paid during the periods for:
Interest	27,698	280
Income taxes	$ 318,983	$ 103,465

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance beginning at Dec. 31, 2018	$ 409,329	$ 4,595,214	$ 4,300,468	$ (344,204)	$ 8,960,807
Balance beginning (in shares) at Dec. 31, 2018	40,932,911
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 89	176,161			176,250
Issuance of stock-based compensation (in shares)	8,914
Compensation expense related to stock options		121,875			121,875
Repurchase of shares	$ (20)	(2,800)			(2,820)
Repurchase of shares (in shares)	(2,000)
Net income (loss)			(85,390)		(85,390)
Balance ending at Mar. 31, 2019	$ 409,398	4,890,450	4,215,078	(344,204)	9,170,722
Balance ending (in shares) at Mar. 31, 2019	40,939,825
Balance beginning at Dec. 31, 2018	$ 409,329	4,595,214	4,300,468	(344,204)	8,960,807
Balance beginning (in shares) at Dec. 31, 2018	40,932,911
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)					644,606
Balance ending at Sep. 30, 2019	$ 422,286	5,985,636	4,945,074	(344,204)	11,008,792
Balance ending (in shares) at Sep. 30, 2019	42,228,658
Balance beginning at Mar. 31, 2019	$ 409,398	4,890,450	4,215,078	(344,204)	9,170,722
Balance beginning (in shares) at Mar. 31, 2019	40,939,825
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 1,164	35,484			36,648
Issuance of stock-based compensation (in shares)	116,386
Compensation expense related to stock options		194,765			194,765
Issuance upon options exercised	$ 650	24,050			24,700
Issuance upon options exercised (in shares)	65,000
Net income (loss)			78,183		78,183
Balance ending at Jun. 30, 2019	$ 411,212	5,144,749	4,293,261	(344,204)	9,505,018
Balance ending (in shares) at Jun. 30, 2019	41,121,211
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 124	43,502			43,626
Issuance of stock-based compensation (in shares)	12,447
Compensation expense related to stock options		324,135			324,135
Issuance of warrants exercised	$ 10,000	440,000			450,000
Issuance of warrants exercised (in shares)	1,000,000
Issuance upon options exercised	$ 950	33,250			34,200
Issuance upon options exercised (in shares)	95,000
Net income (loss)			651,813		651,813
Balance ending at Sep. 30, 2019	$ 422,286	5,985,636	4,945,074	(344,204)	11,008,792
Balance ending (in shares) at Sep. 30, 2019	42,228,658
Balance beginning at Dec. 31, 2019	$ 422,398	6,293,069	4,864,817	(344,204)	11,236,080
Balance beginning (in shares) at Dec. 31, 2019	42,239,788
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 92	59,910			60,002
Issuance of stock-based compensation (in shares)	9,189
Compensation expense related to stock options		300,966			300,966
Repurchase of shares
Issuance upon options exercised	$ 1,750	83,750			85,500
Issuance upon options exercised (in shares)	175,000
Net income (loss)			449,428		449,428
Balance ending at Mar. 31, 2020	$ 424,240	6,737,695	5,314,245	(344,204)	12,131,976
Balance ending (in shares) at Mar. 31, 2020	42,423,977
Balance beginning at Dec. 31, 2019	$ 422,398	6,293,069	4,864,817	(344,204)	11,236,080
Balance beginning (in shares) at Dec. 31, 2019	42,239,788
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)					(377,435)
Balance ending at Sep. 30, 2020	$ 466,718	35,331,483	4,487,382	(344,204)	39,941,379
Balance ending (in shares) at Sep. 30, 2020	46,671,807
Balance beginning at Mar. 31, 2020	$ 424,240	6,737,695	5,314,245	(344,204)	12,131,976
Balance beginning (in shares) at Mar. 31, 2020	42,423,977
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 80	59,922			60,002
Issuance of stock-based compensation (in shares)	7,999
Compensation expense related to stock options		363,851			363,851
Litigation settlement options		347,008			347,008
Litigation settlement share issuance	$ 952	937,142			938,094
Litigation settlement share issuance (in shares)	95,238
Issuance upon options exercised	$ 5,192	5,189			10,381
Issuance upon options exercised (in shares)	519,156
Capital raise	$ 35,937	26,436,043			26,471,980
Capital raise (in shares)	3,593,750
Net income (loss)			(1,076,038)		(1,076,038)
Balance ending at Jun. 30, 2020	$ 466,401	34,886,850	4,238,207	(344,204)	39,247,254
Balance ending (in shares) at Jun. 30, 2020	46,640,120
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock-based compensation	$ 67	59,935			60,002
Issuance of stock-based compensation (in shares)	6,681
Compensation expense related to stock options		346,323			346,323
Issuance upon options exercised	$ 250	(250)
Issuance upon options exercised (in shares)	25,006
Capital raise		38,625			38,625
Net income (loss)			249,175		249,175
Balance ending at Sep. 30, 2020	$ 466,718	$ 35,331,483	$ 4,487,382	$ (344,204)	$ 39,941,379
Balance ending (in shares) at Sep. 30, 2020	46,671,807

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NATURE OF OPERATIONS REPRO MED SYSTEMS, INC. (the “Company,” “KORU Medical,” “we,” “us” or “our”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management. The Company operates as one segment. BASIS OF PRESENTATION The accompanying financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2019 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying financial statements. The accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the periods presented. All such adjustments are of a normal, recurring nature. The Company’s results of operations and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods. CASH AND CASH EQUIVALENTS For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured. CERTIFICATE OF DEPOSIT The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019. INVENTORY Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead. PATENTS Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents. INCOME TAXES Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2017 are subject to examination by income tax authorities. PROPERTY, EQUIPMENT, AND DEPRECIATION Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. STOCK-BASED COMPENSATION The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date. NET INCOME PER COMMON SHARE Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See “NOTE 4 — STOCK-BASED COMPENSATION” for further detail. Three Months Ended September 30, 2020 September 30, 2019 Net income $ 249,175 $ 651,813 Weighted Average Outstanding Shares: Outstanding shares 43,914,542 39,022,298 Option shares includable 204,969 276,110 44,119,511 39,298,408 Net income per share Basic $ 0.01 $ 0.02 Diluted $ 0.01 $ 0.02 Nine Months Ended September 30, 2020 September 30, 2019 Net (loss)/income $ (377,435 ) $ 644,606 Weighted Average Outstanding Shares: Outstanding shares 41,326,815 38,534,021 Option shares includable — (a) 200,062 41,326,815 38,734,083 Net income per share Basic $ (0.01 ) $ 0.02 Diluted $ (0.01 ) $ 0.02 __________ (a) Option shares of 203,121 were not included as the impact is anti-dilutive. USE OF ESTIMATES IN THE FINANCIAL STATEMENTS The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory valuation, and accruals. REVENUE RECOGNITION The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales. The Company generally does not accept return of goods shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred. Provisions for distributor pricing and annual customer growth rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers. The following table summarizes net sales by geography for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Sales Domestic $ 5,372,536 $ 5,856,203 $ 17,459,212 $ 14,308,994 International 707,779 761,194 2,660,016 2,631,493 Total $ 6,080,315 $ 6,617,397 $ 20,119,228 $ 16,940,487 LEASES In February 2016, the FASB issued a standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially unchanged. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard became effective for us on January 1, 2019. The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. See “NOTE 6 — ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure for Fair Value Measurement In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations. FAIR VALUE MEASUREMENTS Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation. The carrying amounts of cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term nature of those instruments. There were no transfers between levels in the fair value hierarchy during the nine months ended September 30, 2020. IMPAIRMENT OF LONG-LIVED ASSETS The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through September 30, 2020. RECLASSIFICATION Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 2 — PROPERTY AND EQUIPMENT Property and equipment consists of the following at: September 30, 2020 December 31, 2019 Furniture, office equipment, and leasehold improvements $ 1,291,985 $ 1,135,107 Manufacturing equipment and tooling 1,856,881 1,295,978 Total property and equipment 3,148,866 2,431,085 Less: accumulated depreciation (1,888,191 ) (1,819,239 ) Property and equipment, net $ 1,260,675 $ 611,846 Depreciation expense was $99,071 and $69,740 for the three months ended September 30, 2020 and 2019, respectively, and $251,084 and $218,328 for the nine months ended September 30, 2020 and 2019, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 3 — COMMITMENTS AND CONTINGENCIES LEGAL PROCEEDINGS The Company has been and may again become involved in legal proceedings, claims and litigation arising in the ordinary course of business. Except as described below, KORU Medical is not presently a party to any litigation or other legal proceeding that is believed to be material to its financial condition. Litigation Refer to Form 10-Q for the quarterly period ended June 30, 2020 regarding the dismissed case with our principal competitor, EMED Technologies Corporation (“EMED”).

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 4 — STOCK-BASED COMPENSATION On June 29, 2016, the Board of Directors amended the Company’s 2015 Stock Option Plan (as amended, the “Plan”) authorizing the Company to grant awards to certain executives, key employees, and consultants under the Plan, which was approved by shareholders at the Annual Meeting of Shareholders held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, may not exceed 6,000,000 pursuant to an amendment to the Plan approved by shareholders on April 23, 2019, at the 2019 Annual Meeting of Shareholders. On May 20, 2020, the Company entered into a Settlement Agreement related to its litigation with EMED as described above in “NOTE 3 — On February 20, 2019, the Board of Directors of the Company approved an increase in compensation for each non-employee director from $25,000 to $50,000 annually effective January 1, 2019, and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock at the end of each fiscal quarter. On September 30, 2019, the Board of Directors of the Company named R. John Fletcher, a current KORU Medical director, as Chairman, replacing Executive Chairman, Daniel S. Goldberger, who remains a non-executive member of KORU Medical’s Board of Directors. In Mr. Fletcher’s role as Chairman, he receives an additional $50,000 in annual compensation, to be paid quarterly in shares of KORU Medical common stock based on the closing price of the stock on the last day of each quarter. Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000 to be paid half in cash and half in stock. The number of shares that were issued totaled 90,604 and was based upon the closing price of the Common Stock of the Company on February 1, 2019, as reported by the OTCQX. These shares were issued on April 3, 2019. 2015 STOCK OPTION PLAN, as amended Time Based Stock Options The per share weighted average fair value of stock options granted during the nine months ended September 30, 2020 and September 30, 2019 was $6.53 and $1.33, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2020 and September 30, 2019. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. September 30, 2020 2019 Dividend yield 0.00% 0.00% Expected Volatility 62.11 – 62.18% 56.10 – 60.70% Weighted-average volatility — — Expected dividends — — Expected term (in years) 10 Years 10 Years Risk-free rate 0.63 – 0.64% 1.60 – 2.72% The following table summarizes the status of the Plan with respect to time based stock options: Nine Months Ended September 30, 2020 2019 Shares Weighted Shares Weighted Outstanding at January 1 3,647,000 $ 1.32 2,419,000 $ 1.00 Granted 360,000 $ 9.54 1,650,000 $ 1.92 Exercised 747,006 $ 0.65 160,000 $ 0.37 Forfeited 200,000 $ 2.09 12,000 $ 0.87 Outstanding at September 30 3,059,994 $ 2.40 3,897,000 $ 1.41 Options exercisable at September 30 1,009,629 $ 1.36 1,037,885 $ 0.81 Weighted average fair value of options granted during the period — $ 6.53 — $ 1.33 Stock-based compensation expense — $ 572,775 — $ 473,139 Total stock-based compensation expense totaled $572,775 and $473,139 for the nine months ended September 30, 2020 and 2019, respectively. Cash received from option exercises for the nine months ended September 30, 2020 and 2019 was $95,880 and $58,900, respectively. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2020 and 2019 was $6.53 and $1.33, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2020 and 2019 was $296,226 and $30,022, respectively. The following table presents information pertaining to options outstanding at September 30, 2020: Range of Exercise Price Number Weighted Weighted Number Weighted $0.50 – 9.76 3,059,994 7.5 years $ 2.40 1,009,629 $ 1.36 As of September 30, 2020, there was $3,679,084 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 48 months. The total fair value of shares vested as of September 30, 2020 and 2019, was $874,041 and $506,729, respectively. Performance Based Stock Options The per share weighted average fair value of stock options granted during the nine months ended September 30, 2020 and 2019 was zero and $1.16, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the nine months ended September 30, 2020 and September 30, 2019. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. September 30, 2020 2019 Dividend yield — 0.00% Expected Volatility — 58.90% Weighted-average volatility — — Expected dividends — — Expected term (in years) — 10 Years Risk-free rate — 2.07% The following table summarizes the status of the Plan with respect to performance based stock options: Nine Months Ended September 30, 2020 2019 Shares Weighted Shares Weighted Outstanding at January 1 1,000,000 $ 1.70 — $ — Granted — $ — 1,000,000 $ 1.70 Exercised — $ — — $ — Forfeited — $ — — $ — Outstanding at September 30 1,000,000 $ 1.70 1,000,000 $ 1.70 Options exercisable at September 30 333,333 $ 1.70 — $ — Weighted average fair value of options granted during the period — $ — — $ 1.16 Stock-based compensation expense — $ 438,365 — $ 167,636 Total performance stock-based compensation expense totaled $438,365 and $167,636 for the nine months ended September 30, 2020 and 2019, respectively. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2020 and 2019, was zero and $1.16, respectively. The following table presents information pertaining to performance based options outstanding at September 30, 2020. Range of Exercise Price Number Weighted Weighted Number Weighted $1.70 1,000,000 8.7 years $ 1.70 333,333 $ 1.70 As of September 30, 2020, there was $430,833 of total unrecognized compensation cost related to non-vested performance share option based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 31 months. The total fair value of shares vested as of September 30, 2020 and 2019 was $387,520 and zero, respectively.

DEBT OBLIGATIONS

DEBT OBLIGATIONS	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
DEBT OBLIGATIONS	NOTE 5 — DEBT OBLIGATIONS On February 8, 2018, the Company issued a promissory note (the “Original Note”) to KeyBank National Association (“KeyBank”) in the amount of $1.5 million as a variable rate revolving line of credit loan due on demand with an interest rate of LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. On September 25, 2018, KeyBank released the certificate of deposit as collateral for the loan and the Company executed a Commercial Security Agreement as collateral for the loan. On April 14, 2020, the Company issued a promissory note to KeyBank in the aggregate principal amount of $3.5 million (the “Note”) as an extension of its line of credit, replacing its current line of credit agreement and Original Note. The Company drew on the additional $2.0 million on April 23, 2020. The Original Note was in the form of a variable rate revolving line of credit with an interest rate of LIBOR plus 2.25%. The $3.5 million Note is in the form of a variable rate non-disclosable revolving line of credit with an interest rate of Prime Rate announced by the Bank minus 0.75%. Interest is due monthly, and all principal and unpaid interest is due on June 1, 2021. The $3.5 million Note may be prepaid at any time prior to maturity with no prepayment penalties. The $3.5 million Note contains events of default and other provisions customary for a loan of this type. In connection with the Note, the Company entered into a Commercial Security Agreement with the Bank dated April 14, 2020 (the “Security Agreement”), pursuant to which the Company granted a security interest in substantially all assets of the Company to secure the obligations of the Company under the Note. The Security Agreement contains terms and conditions typical for the granting of security interests of this kind. The Company had no amount outstanding against the line of credit as of September 30, 2020. On April 20, 2020, the Company entered into a Loan Agreement with the Bank (the “PPP Loan Agreement”) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), providing for a loan in the principal amount of $1,476,508 (the “PPP Loan”). The PPP Loan was funded on April 27, 2020. On May 13, 2020, the Company returned the funds it received. On April 27, 2020, the Company entered into a Progress Payment Loan and Security Agreement (“PPLSA”) and a Master Security Agreement (the “MSA”), each dated as of April 20, 2020, with Key Equipment Finance, a division of the Bank (“KEF”), to provide up to $2.5 million in financing for equipment purchases from third party vendors. The PPLSA allows the Company to make draws with KEF to make certain payments to the equipment suppliers prior to the commencement of periodic payments under a term loan. Each draw under the PPLSA will bear interest at a variable rate equal to the then-current Prime Rate and will be secured by the financed equipment under the MSA. At the end of each calendar quarter or year, the advances made under the PPLSA will be converted to term loans, subject to KEF’s approval of the equipment and certain other closing conditions being met. Once the draws under the PPLSA are converted into a term loan, each promissory note will bear interest at a fixed rate of 4.07% per annum, subject to adjustment based on KEF’s cost of funds, with principal and interest payable in 84 equal consecutive monthly installments. Each fixed rate installment promissory note may be prepaid, subject to a penalty if prepaid before the fifth anniversary of its issuance. As of September 30, 2020, the Company had no amount outstanding against the PPLSA.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
LEASES	NOTE 6 — LEASES We have finance and operating leases for our corporate office and certain office and computer equipment. Our leases have remaining lease terms of 1 to 3 years, some of which include options to extend the leases annually and some with options to terminate the leases within 1 year. The components of lease expense were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating lease cost $ 37,921 $ 37,922 $ 113,764 $ 111,672 Short-term lease cost 19,846 5,535 33,535 18,196 Total lease cost $ 57,767 $ 43,457 $ 147,299 $ 129,868 Finance lease cost: Amortization of right-of-use assets $ 791 $ 1,061 $ 4,502 $ 3,182 Interest on lease liabilities 47 47 199 178 Total finance lease cost $ 838 $ 1,108 $ 4,701 $ 3,360 Supplemental cash flow information related to leases was as follows: Nine Months Ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 113,764 $ 111,672 Financing cash flows from finance leases 4,502 3,122 Supplemental balance sheet information related to leases was as follows: September 30, December 31, Operating Leases Operating lease right-of-use assets $ 271,679 $ 373,734 Operating lease current liabilities 140,450 136,888 Operating lease long term liabilities 131,229 236,846 Total operating lease liabilities $ 271,679 $ 373,734 Finance Leases Property and equipment, at cost $ 12,725 $ 12,725 Accumulated depreciation (9,344 ) (4,837 ) Property and equipment, net $ 3,381 $ 7,888 Finance lease current liabilities 3,026 5,296 Finance lease long term liabilities 414 2,646 Total finance lease liabilities $ 3,440 $ 7,942 September 30, December 31, Weighted Average Remaining Lease Term Operating leases 1.6 Years 2.4 Years Finance leases 1 Year 1.3 Years Weighted Average Discount Rate Operating leases 4.75% 4.75% Finance leases 4.75% 4.75% Maturities of lease liabilities are as follows: Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the nine months ended September 30, 2020) $ 37,922 $ 832 2021 149,476 2,705 2022 97,256 — 2023 — — 2024 — — 2025 — — Thereafter — — Total undiscounted lease payments 284,654 3,537 Less: imputed interest (12,975 ) (97 ) Total lease liabilities $ 271,679 $ 3,440

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 — RELATED PARTY TRANSACTIONS BUILDING LEASE Mark Pastreich, a former director through April 2019, is a principal in the entity that owns the building leased by us for our corporate headquarters and manufacturing facility at 24 Carpenter Road, Chester, New York 10918. On February 28, 2019, we completed year twenty of a twenty-year lease with monthly lease payments of $11,042. On November 14, 2017, we executed a lease extension, which calls for six-month extensions beginning March 1, 2019 with the option to renew six times at a monthly lease amount of $12,088. The Company exercised four of the six additional renewal options for September 1, 2019 through August 31, 2021. The lease payments were $36,264 for both three months ended September 30, 2020 and 2019, and $108,792 and $106,700 for the nine months ended September 30, 2020 and 2019, respectively. The Company also paid property taxes in the amount of $12,546 and $13,749 for three months ended September 30, 2020 and 2019, respectively and $39,205 and $39,165 for the nine months ended September 30, 2020 and 2019, respectively.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
EQUITY	NOTE 8 — EQUITY On June 18, 2020, the Company entered into a Purchase Agreement with Piper Sandler & Co. and Canaccord Genuity LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 3,125,000 shares of its common stock. Under the terms of the Purchase Agreement, the Company granted to the Underwriters an option, exercisable for a period of 30 days, to purchase up to an additional 468,750 shares of the Company’s common stock, which the Underwriters exercised in full on June 19, 2020. The Underwriters purchased the shares pursuant to the Purchase Agreement, including the shares subject to the option, at a price of $7.52 per share. Proceeds to the Company, net of discounts, commissions, fees and expenses, were $26.5 million.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 9 — SUBSEQUENT EVENT On November 11, 2020, the Company entered into a Manufacturing and Supply Agreement with Command Medical Products, Inc. (“Command”), pursuant to which Command has agreed to manufacture and supply the Company’s subassemblies, needle sets and tubing products pursuant to the Company’s specifications and purchase orders. The first binding purchase order pursuant to the Manufacturing and Supply Agreement is expected to be made within the next ten days (the “Effective Date”). The Manufacturing and Supply Agreement provides for a term of five years from the Effective Date. Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the Agreement. If the Company terminates the Manufacturing and Supply Agreement other than for those reasons within the first three years from the Effective Date, the Company is obligated to pay an early termination fee to Command. The Manufacturing and Supply Agreement also includes customary provisions relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling and transport, intellectual property, confidentiality and indemnification.

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS REPRO MED SYSTEMS, INC. (the “Company,” “KORU Medical,” “we,” “us” or “our”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management. The Company operates as one segment.
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying financial statements should be read in conjunction with the Company’s annual report on Form 10-K for the year ended December 31, 2019 (“Annual Report”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted from the accompanying financial statements. The accompanying year-end balance sheet was derived from the audited financial statements included in the Annual Report. The accompanying interim financial statements are unaudited and reflect all adjustments which are in the opinion of management necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the periods presented. All such adjustments are of a normal, recurring nature. The Company’s results of operations and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.
CERTIFICATE OF DEPOSIT	CERTIFICATE OF DEPOSIT The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019.
INVENTORY	INVENTORY Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.
PATENTS	PATENTS Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.
INCOME TAXES	INCOME TAXES Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2017 are subject to examination by income tax authorities.
PROPERTY, EQUIPMENT, AND DEPRECIATION	PROPERTY, EQUIPMENT, AND DEPRECIATION Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company maintains a stock option plan under which it grants stock options to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted for director fees are recorded at the fair value of the shares at the grant date.
NET INCOME PER COMMON SHARE	NET INCOME PER COMMON SHARE Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See “NOTE 4 — STOCK-BASED COMPENSATION” for further detail. Three Months Ended September 30, 2020 September 30, 2019 Net income $ 249,175 $ 651,813 Weighted Average Outstanding Shares: Outstanding shares 43,914,542 39,022,298 Option shares includable 204,969 276,110 44,119,511 39,298,408 Net income per share Basic $ 0.01 $ 0.02 Diluted $ 0.01 $ 0.02 Nine Months Ended September 30, 2020 September 30, 2019 Net (loss)/income $ (377,435 ) $ 644,606 Weighted Average Outstanding Shares: Outstanding shares 41,326,815 38,534,021 Option shares includable — (a) 200,062 41,326,815 38,734,083 Net income per share Basic $ (0.01 ) $ 0.02 Diluted $ (0.01 ) $ 0.02 __________ (a) Option shares of 203,121 were not included as the impact is anti-dilutive.
USE OF ESTIMATES IN THE FINANCIAL STATEMENTS	USE OF ESTIMATES IN THE FINANCIAL STATEMENTS The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to asset lives, valuation allowances, inventory valuation, and accruals.
REVENUE RECOGNITION	REVENUE RECOGNITION The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales. The Company generally does not accept return of goods shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred. Provisions for distributor pricing and annual customer growth rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it is probable the annual growth target will be achieved. Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers. The following table summarizes net sales by geography for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Sales Domestic $ 5,372,536 $ 5,856,203 $ 17,459,212 $ 14,308,994 International 707,779 761,194 2,660,016 2,631,493 Total $ 6,080,315 $ 6,617,397 $ 20,119,228 $ 16,940,487
LEASES	LEASES In February 2016, the FASB issued a standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current GAAP, while our accounting for capital leases remains substantially unchanged. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard became effective for us on January 1, 2019. The standard had a material impact on our balance sheets but did not have a material impact on our statements of operations. See “NOTE 6 —
ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED	ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure for Fair Value Measurement In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract
ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED	ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation. The carrying amounts of cash and cash equivalents, accounts receivable, prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term nature of those instruments. There were no transfers between levels in the fair value hierarchy during the nine months ended September 30, 2020.
IMPAIRMENT OF LONG-LIVED ASSETS	IMPAIRMENT OF LONG-LIVED ASSETS The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No impairment losses have been recorded through September 30, 2020.
RECLASSIFICATION	RECLASSIFICATION Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2020
Nature Of Operations And Summary Of Significant Accounting Policies
Schedule of net income per common share	Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See “NOTE 4 — STOCK-BASED COMPENSATION” for further detail. Three Months Ended September 30, 2020 September 30, 2019 Net income $ 249,175 $ 651,813 Weighted Average Outstanding Shares: Outstanding shares 43,914,542 39,022,298 Option shares includable 204,969 276,110 44,119,511 39,298,408 Net income per share Basic $ 0.01 $ 0.02 Diluted $ 0.01 $ 0.02 Nine Months Ended September 30, 2020 September 30, 2019 Net (loss)/income $ (377,435 ) $ 644,606 Weighted Average Outstanding Shares: Outstanding shares 41,326,815 38,534,021 Option shares includable — (a) 200,062 41,326,815 38,734,083 Net income per share Basic $ (0.01 ) $ 0.02 Diluted $ (0.01 ) $ 0.02 __________ (a) Option shares of 203,121 were not included as the impact is anti-dilutive.
Schedule of net sales by geography	The following table summarizes net sales by geography for the three and nine months ended September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Sales Domestic $ 5,372,536 $ 5,856,203 $ 17,459,212 $ 14,308,994 International 707,779 761,194 2,660,016 2,631,493 Total $ 6,080,315 $ 6,617,397 $ 20,119,228 $ 16,940,487

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment consists of the following at: September 30, 2020 December 31, 2019 Furniture, office equipment, and leasehold improvements $ 1,291,985 $ 1,135,107 Manufacturing equipment and tooling 1,856,881 1,295,978 Total property and equipment 3,148,866 2,431,085 Less: accumulated depreciation (1,888,191 ) (1,819,239 ) Property and equipment, net $ 1,260,675 $ 611,846

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of fair value of the stock options granted Black-Scholes option valuation model	The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. September 30, 2020 2019 Dividend yield 0.00% 0.00% Expected Volatility 62.11 – 62.18% 56.10 – 60.70% Weighted-average volatility — — Expected dividends — — Expected term (in years) 10 Years 10 Years Risk-free rate 0.63 – 0.64% 1.60 – 2.72%
Schedule of stock option plan	The following table summarizes the status of the Plan with respect to time based stock options: Nine Months Ended September 30, 2020 2019 Shares Weighted Shares Weighted Outstanding at January 1 3,647,000 $ 1.32 2,419,000 $ 1.00 Granted 360,000 $ 9.54 1,650,000 $ 1.92 Exercised 747,006 $ 0.65 160,000 $ 0.37 Forfeited 200,000 $ 2.09 12,000 $ 0.87 Outstanding at September 30 3,059,994 $ 2.40 3,897,000 $ 1.41 Options exercisable at September 30 1,009,629 $ 1.36 1,037,885 $ 0.81 Weighted average fair value of options granted during the period — $ 6.53 — $ 1.33 Stock-based compensation expense — $ 572,775 — $ 473,139
Schedule of information pertaining to options outstanding	The following table presents information pertaining to options outstanding at September 30, 2020: Range of Exercise Price Number Weighted Weighted Number Weighted $0.50 – 9.76 3,059,994 7.5 years $ 2.40 1,009,629 $ 1.36
Schedule of performance base share options	The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued. September 30, 2020 2019 Dividend yield — 0.00% Expected Volatility — 58.90% Weighted-average volatility — — Expected dividends — — Expected term (in years) — 10 Years Risk-free rate — 2.07%
Schedule of performance base options outstanding	The following table summarizes the status of the Plan with respect to performance based stock options: Nine Months Ended September 30, 2020 2019 Shares Weighted Shares Weighted Outstanding at January 1 1,000,000 $ 1.70 — $ — Granted — $ — 1,000,000 $ 1.70 Exercised — $ — — $ — Forfeited — $ — — $ — Outstanding at September 30 1,000,000 $ 1.70 1,000,000 $ 1.70 Options exercisable at September 30 333,333 $ 1.70 — $ — Weighted average fair value of options granted during the period — $ — — $ 1.16 Stock-based compensation expense — $ 438,365 — $ 167,636
Schedule of information pertaining to performance base options outstanding	The following table presents information pertaining to performance based options outstanding at September 30, 2020. Range of Exercise Price Number Weighted Weighted Number Weighted $1.70 1,000,000 8.7 years $ 1.70 333,333 $ 1.70

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating lease cost $ 37,921 $ 37,922 $ 113,764 $ 111,672 Short-term lease cost 19,846 5,535 33,535 18,196 Total lease cost $ 57,767 $ 43,457 $ 147,299 $ 129,868 Finance lease cost: Amortization of right-of-use assets $ 791 $ 1,061 $ 4,502 $ 3,182 Interest on lease liabilities 47 47 199 178 Total finance lease cost $ 838 $ 1,108 $ 4,701 $ 3,360
Schedule of cash flow information related to leases	Supplemental cash flow information related to leases was as follows: Nine Months Ended September 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 113,764 $ 111,672 Financing cash flows from finance leases 4,502 3,122
Schdeule of balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows: September 30, December 31, Operating Leases Operating lease right-of-use assets $ 271,679 $ 373,734 Operating lease current liabilities 140,450 136,888 Operating lease long term liabilities 131,229 236,846 Total operating lease liabilities $ 271,679 $ 373,734 Finance Leases Property and equipment, at cost $ 12,725 $ 12,725 Accumulated depreciation (9,344 ) (4,837 ) Property and equipment, net $ 3,381 $ 7,888 Finance lease current liabilities 3,026 5,296 Finance lease long term liabilities 414 2,646 Total finance lease liabilities $ 3,440 $ 7,942 September 30, December 31, Weighted Average Remaining Lease Term Operating leases 1.6 Years 2.4 Years Finance leases 1 Year 1.3 Years Weighted Average Discount Rate Operating leases 4.75% 4.75% Finance leases 4.75% 4.75%
Schedule of maturities of lease liabilities	Maturities of lease liabilities are as follows: Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the nine months ended September 30, 2020) $ 37,922 $ 832 2021 149,476 2,705 2022 97,256 — 2023 — — 2024 — — 2025 — — Thereafter — — Total undiscounted lease payments 284,654 3,537 Less: imputed interest (12,975 ) (97 ) Total lease liabilities $ 271,679 $ 3,440

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020		Sep. 30, 2019
Accounting Policies [Abstract]
Net income	$ 249,175	$ (1,076,038)	$ 449,428	$ 651,813	$ 78,183	$ (85,390)	$ (377,435)		$ 644,606
Weighted Average Outstanding Shares:
Outstanding shares	43,914,542			39,022,298			41,326,815		38,534,021
Option shares includable	204,969			276,110				[1]	200,062
Total	44,119,511			39,298,408			41,326,815		38,734,083
Net income per share
Basic (in dollars per share)	$ 0.01			$ 0.02			$ (0.01)		$ 0.02
Diluted (in dollars per share)	$ 0.01			$ 0.02			$ (0.01)		$ 0.02
[1]	Option shares of 203,121 were not included as the impact is anti-dilutive.

NATURE OF OPERATIONS AND SUMM_5

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net sales	$ 6,080,315	$ 6,617,397	$ 20,119,228	$ 16,940,487
Domestic [Member]
Net sales	5,372,536	5,856,203	17,459,212	14,308,994
International [Member]
Net sales	$ 707,779	$ 761,194	$ 2,660,016	$ 2,631,493

NATURE OF OPERATIONS AND SUMM_6

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	9 Months Ended
	Sep. 30, 2020USD ($)Segmentshares
Number of segments | Segment	1
FDIC cash uninsured amount | $	$ 250,000
Option [Member]
Anti-dilutive shares | shares	203,121
Certificates Of Deposit [Member]
Interest rate	1.73%
Certificate of deposit, matured date	May 31, 2019

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 3,148,866	$ 2,431,085
Less: accumulated depreciation	(1,888,191)	(1,819,239)
Property and equipment, net	1,260,675	611,846
Furniture, Office Equipment, and Leasehold Improvements [Member]
Property and equipment, gross	1,291,985	1,135,107
Manufacturing Equipment And Tooling [Member]
Property and equipment, gross	$ 1,856,881	$ 1,295,978

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 99,071	$ 69,740	$ 251,084	$ 218,328

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - 2015 Stock Option Plan [Member] - Time Based Shares Options [Member] - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Dividend yield	0.00%	0.00%
Weighted-average volatility
Expected dividends
Expected term (in years)	10 years	10 years
Minimum [Member]
Expected Volatility	62.11%	56.10%
Risk-free rate	0.63%	1.60%
Maximum [Member]
Expected Volatility	62.18%	60.70%
Risk-free rate	0.64%	2.72%

STOCK-BASED COMPENSATION (Det_2

STOCK-BASED COMPENSATION (Details 1) - 2015 Stock Option Plan [Member] - Time Based Shares Options [Member] - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	3,647,000	2,419,000
Granted	360,000	1,650,000
Exercised	747,006	160,000
Forfeited	200,000	12,000
Outstanding at ending	3,059,994	3,897,000
Options exercisable at ending	1,009,629	1,037,885
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 1.32	$ 1
Granted	9.54	1.92
Exercised	0.65	0.37
Forfeited	2.09	0.87
Outstanding at ending	2.4	1.41
Options exercisable at ending	1.36	0.81
Weighted average fair value of options granted during the period	$ 6.53	$ 1.33
Stock-based compensation expense	$ 572,775	$ 473,139

STOCK-BASED COMPENSATION (Det_3

STOCK-BASED COMPENSATION (Details 2) - 2015 Stock Option Plan [Member] - $ 0.50 - 9.76 [Member] - Time Based Shares Options [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number Outstanding | shares	3,059,994
Weighted Average Remaining Contractual Term	7 years 6 months
Weighted Average Exercise Price | $ / shares	$ 2.40
Number Exercisable | shares	1,009,629
Weighted Average Exercise Price | $ / shares	$ 1.36

STOCK-BASED COMPENSATION (Det_4

STOCK-BASED COMPENSATION (Details 3) - 2015 Stock Option Plan [Member] - Performance Based Share Options [Member] - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Dividend yield		0.00%
Expected Volatility		58.90%
Weighted-average volatility
Expected dividends
Expected term (in years)		10 years
Risk-free rate		2.07%

STOCK-BASED COMPENSATION (Det_5

STOCK-BASED COMPENSATION (Details 4) - 2015 Stock Option Plan [Member] - Performance Based Share Options [Member] - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	1,000,000
Granted		1,000,000
Exercised
Forfeited
Outstanding at ending	1,000,000	1,000,000
Options exercisable at ending	333,333
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 1.70
Granted		1.70
Exercised
Forfeited
Outstanding at ending	1.70	1.70
Options exercisable at ending	1.70
Weighted average fair value of options granted during the period		$ 1.16
Stock-based compensation expense	$ 438,365	$ 167,636

STOCK-BASED COMPENSATION (Det_6

STOCK-BASED COMPENSATION (Details 5) - 2015 Stock Option Plan [Member] - Performance Based Share Options [Member] - $1.70 [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number Outstanding | shares	1,000,000
Weighted Average Remaining Contractual Term	8 years 8 months 12 days
Weighted Average Exercise Price | $ / shares	$ 1.70
Number Exercisable | shares	333,333
Weighted Average Exercise Price | $ / shares	$ 1.70

STOCK-BASED COMPENSATION (Det_7

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Sep. 30, 2019	May 20, 2019	Apr. 23, 2019	Apr. 02, 2019	Feb. 20, 2019	Feb. 02, 2019	Jan. 02, 2019	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Number of shares authorized to employees									60,000
Settlement Agreement [Member] | EMED Technologies Corporation [Member]
Description of vesting rights		The Company issued to EMED (i) 95,238 restricted stock units, which vested on May 21, 2020 and 95,238 restricted stock units vesting on January 1, 2021, and (ii) an option to purchase up to 400,000 shares of the Company’s common stock at an exercise price of $11.21 per share prior to February 1, 2021, which can be settled in cash in lieu of common stock at the Company’s sole discretion, provided that the number of shares of common stock and/or amount of cash paid by the Company upon exercise will be capped at a value of $16.21 per share. The option was recorded at $347,008, the estimated fair value of the option using the Black-Scholes option pricing model with a volatility rate of 52.68% and a risk-free rate of 0.17%.
Non-cash expense								$ 2,200,000
Independent Directors [Member]
Description of payment terms					Paid quarterly half in cash and half in common stock
Annually compensation paid per director					$ 25,000		$ 50,000
Annually additional payment for agreement					$ 10,000
Mr. R. John Fletcher [Member]
Annually compensation paid per director	$ 50,000
Chief Executive Officer, Mr. Goldberger [Member] | Employment Agreement [Member]
Number of shares authorized to employees						90,604
Description of payment terms				A performance bonus in the amount of $270,000 to be paid half in cash and half in stock.
2015 Stock Option Plan [Member]
Number of shares authorized to employees			6,000,000
2015 Stock Option Plan [Member] | Time Based Shares Options [Member]
Weighted average grant date fair value of stock options									$ 6.53	$ 1.33
Allocated stock-based compensation expense									$ 572,775	$ 473,139
Total unrecognized compensation cost									$ 3,679,084
Weighted-average period (in years)									48 months
Total fair value of shares vested									$ 874,041	$ 506,729
Number of options outstanding	3,897,000								3,059,994	3,897,000	3,647,000	2,419,000
Cash received from option exercises									$ 95,880	$ 58,900
Number of options exercised									296,226	30,022
2015 Stock Option Plan [Member] | Performance Based Share Options [Member]
Weighted average grant date fair value of stock options										$ 1.16
Allocated stock-based compensation expense									$ 438,365	$ 167,636
Weighted-average grant-date fair value options granted										1,160,000
Total unrecognized compensation cost									$ 430,833
Weighted-average period (in years)									31 months
Total fair value of shares vested									$ 387,520	$ 0
Number of options outstanding	1,000,000								1,000,000	1,000,000	1,000,000

DEBT OBLIGATIONS (Details Narra

DEBT OBLIGATIONS (Details Narrative) - USD ($)	Apr. 27, 2020	Apr. 20, 2020	Apr. 14, 2020	Feb. 08, 2018	Sep. 30, 2020	Apr. 23, 2020	Jun. 30, 2019
PPP Loan Agreement [Member]
Loans, principal amount		$ 1,476,508
Loans, funded date		Apr. 27, 2020
Key Equipment Finance [Member] | Progress Payment Loan and Security Agreement And Master Security Agreement [Member]
Interest rate terms	Fixed rate of 4.07% per annum
Loans, principal amount	$ 2,500,000
Principal and interest payable terms	84 equal consecutive monthly installments.
Promissory Note [Member] | KeyBank National Association [Member]
Face amount			$ 3,500,000			$ 2,000,000
Interest rate terms			LIBOR plus 2.25%
Promissory Note [Member] | Non-Disclosable Revolving Line of Credit [Member] | KeyBank National Association [Member]
Face amount			$ 3,500,000
Interest rate terms			Prime Rate announced by the Bank minus 0.75%
Debt instrument, principal and unpaid interest due			Jun. 1, 2021
Debt instrument, prepaid terms			Any time prior to maturity with no prepayment penalties.
KeyBank National Association [Member] | Promissory Note [Member] | Revolving Credit Facility [Member]
Face amount				$ 1,500,000	$ 0		$ 0
Interest rate terms				LIBOR plus 2.25%
Description collateral				collateralized with a certificate of deposit
Collateral amount				$ 1,500,000

LEASES (Details)

LEASES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 37,921	$ 37,922	$ 113,764	$ 111,672
Short-term lease cost	19,846	5,535	33,535	18,196
Total lease cost	57,767	43,457	147,299	129,868
Finance lease cost:
Amortization of right-of-use assets	791	1,061	4,502	3,182
Interest on lease liabilities	47	47	199	178
Total finance lease cost	$ 838	$ 1,108	$ 4,701	$ 3,360

LEASES (Details 1)

LEASES (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 113,764	$ 111,672
Financing cash flows from finance leases	$ 4,502	$ 3,122

LEASES (Details 2)

LEASES (Details 2) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Operating Leases
Operating lease right-of-use assets	$ 271,679	$ 373,734
Operating lease current liabilities	140,450	136,888
Operating lease long term liabilities	131,229	236,846
Total operating lease liabilities	271,679	373,734
Finance Leases
Property and equipment, at cost	12,725	12,725
Accumulated depreciation	(9,344)	(4,837)
Property and equipment, net	3,381	7,888
Finance lease current liabilities	3,026	5,296
Finance lease long term liabilities	414	2,646
Total finance lease liabilities	$ 3,440	$ 7,942

LEASES (Details 3)

LEASES (Details 3)	Sep. 30, 2020	Jun. 30, 2019
Weighted Average Remaining Lease Term
Operating leases	1 year 7 months 6 days	2 years 4 months 24 days
Finance leases	1 year	1 year 3 months 18 days
Weighted Average Discount Rate
Operating leases	4.75%	4.75%
Finance leases	4.75%	4.75%

LEASES (Details 4)

LEASES (Details 4) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Operating Leases
2020	$ 37,922
2021	149,476
2022	97,256
2023
2024
2025
Thereafter
Total undiscounted lease payments	284,654
Less: imputed interest	(12,975)
Total operating lease liabilities	271,679	$ 373,734
Finance Leases
2020	832
2021	2,705
2022
2023
2024
2025
Thereafter
Total lease payments	3,537
Less: imputed interest	(97)
Total finance lease liabilities	$ 3,440	$ 7,942

LEASES (Details Narrative)

LEASES (Details Narrative)	9 Months Ended
	Sep. 30, 2020
Operating lease, options to terminate	1 year
Minimum [Member]
Operating lease, renewal term	1 year
Maximum [Member]
Operating lease, renewal term	3 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - Lease Agreement [Member] - Building [Member] - Mr. Mark Pastreich [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 01, 2019	Feb. 28, 2019
Monthly lease payments					$ 12,088	$ 11,042
Lease payments	$ 36,264	$ 36,264	$ 108,792	$ 106,700
Property taxes paid	$ 12,546	$ 13,749	$ 39,205	$ 39,165

EQUITY (Details Narrative)

EQUITY (Details Narrative) - Purchase Agreement [Member] - Piper Sandler & Co. and Canaccord Genuity LLC [Member] - Common Stock [Member]	1 Months Ended
	Jun. 18, 2020USD ($)$ / sharesshares
Number of shares issued (in shares)	3,125,000
Additional number of shares issued (in shares)	468,750
Share price (in dollars per share) | $ / shares	$ 7.52
Proceeds from issuance | $	$ 26,500,000
Option excercise date	Jun. 19, 2020
Option excercise period	30 days

SUBSEQUENT EVENT (Details Narra

SUBSEQUENT EVENT (Details Narrative) - Manufacturing And Supply Agreement [Member] - Command Medical Products Inc [Member] - Subsequent Event [Member]	Nov. 11, 2020
Decription of agreement	The first binding purchase order pursuant to the Manufacturing and Supply Agreement is expected to be made within the next ten days (the “Effective Date”).
Agreement term	5 years